Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
- Source:
Cancer [Cancer] 1978 Jun; Vol. 41 (6), pp. 2456-63.
- Publication Type:
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
- Language:
English
- Additional Information
- Source:
Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Print ISSN: 0008-543X (Print) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
- Publication Information:
Publication: <2005- >: Hoboken, NJ : Wiley
Original Publication: New York [etc.] Published for the American Cancer Society by J. Wiley [etc.]
- Subject Terms:
- Abstract:
Eighteen patients with multiple recurrences of malignant melanoma without evident distant spread were randomly assigned to treatment with either intralesional Bacillus Calmette-Guerin (BCG) or intralesional dinitrochlorobenzene (DNCB). Both agents were able to destroy approximately 90% of the injected intradermal nodules. Intradermal disease was more easily obliterated than subcutaneous disease with intralesional treatment with either agent, and local control of satellitosis with elimination of all clinically evident tumor was achieved in the patients who had intradermal without subcutaneous satellitosis, regardless of whether the patient was receiving BCG or DNCB. The clinical courses of the treated patients were essentially the same. Although PHA reactivity was depressed, the patients in both groups were responsive to recall and melanoma skin test antigens, demonstrated leukocyte migration inhibition with melanoma antigen and were generally within normal limits when assayed for 29 degrees C E rosettes. Our study demonstrated a dramatic difference in toxicity between the two intralesional agents without a similar difference in therapeutic efficacy or immune testing.
- Accession Number:
0 (Antigens)
0 (Antigens, Neoplasm)
0 (BCG Vaccine)
0 (Dinitrochlorobenzene)
0 (Nitrobenzenes)
- Publication Date:
Date Created: 19780601 Date Completed: 19780901 Latest Revision: 20201212
- Publication Date:
20231215
- Accession Number:
10.1002/1097-0142(197806)41:6<2456::aid-cncr2820410654>3.0.co;2-b
- Accession Number:
657108
No Comments.